PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical
News

Pfizer and GSK to battle for share of new RSV vaccine market, says GlobalData

The European Commission (EC) recently approved GSK's novel vaccine, Arexvy, for the prevention of lower respiratory tract infections (LRTI) caused by a respiratory s...
Continue Reading →
News

Canton of Geneva supports Connect in Pharma 2023

Geneva’s position as a leading European life science hub makes it the ideal choice for Connect in Pharma / The Canton of Geneva has announced its official s...
Continue Reading →
News

AstraZeneca’s Tagrisso delivers positive results

The company’s phase 3 study showed treatment with Tagrisso reduced the risk of death by over half. AstraZeneca’s Tagrisso has delivered positive results from its ...
Continue Reading →
News

Element to increases lab equipment presence

Element – a testing, inspection and certification company – has created a lab solutions division within its life sciences business unit. The new division aims to ...
Continue Reading →
News

BioInvent receives Investigational New Drug approval for monoclonal antibody BI-1910

BI-1910 is now the second of the company's anti-tumour necrosis factor receptor 2 programmes to enter clinical development. Swedish clinical-stage biotech company...
Continue Reading →
News

NICE recommends Pfizer’s rimegepant for preventing episodic migraine attacks

The final draft guidance recommends rimegepant for adults who have at least four migraine attacks per month, but less than 15. The National Institute for Care and...
Continue Reading →
News

FDA approves ANDA of 20mg generic Nitisinone capsules

Nitisinone capsules are indicated for patients with hereditary tyrosinemia type 1 in combination with dietary restriction of tyrosine and phenylalanine. Analog Ph...
Continue Reading →
News

Lonza to acquire Synaffix to strengthen ADC development

Synaffix’s technology platform is intended to enhance and extend Lonza’s integrated ADC services. Global manufacturer for the pharmaceutical, biotech and nutraceu...
Continue Reading →
News

Scarlet Therapeutics gains funding for blood cell platform

Vital financing will allow the company to build a pipeline of novel therapies targeting serious conditions. Scarlet Therapeutics – a company focused on developing...
Continue Reading →
News

Positive data for AnaMar’s fibrosis therapy

Receptor antagonist AM1476 was developed as an anti-fibrotic treatment for lung and skin disorders. AnaMar has announced positive results from its phase 1 researc...
Continue Reading →

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026